for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalyst Biosciences Inc

CBIO.OQ

Latest Trade

5.21USD

Change

-0.08(-1.51%)

Volume

54,503

Today's Range

5.19

 - 

5.49

52 Week Range

4.52

 - 

11.28

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.29
Open
5.33
Volume
54,503
3M AVG Volume
2.59
Today's High
5.49
Today's Low
5.19
52 Week High
11.28
52 Week Low
4.52
Shares Out (MIL)
12.04
Market Cap (MIL)
63.70
Forward P/E
-1.17
Dividend (Yield %)
--

Next Event

Catalyst Biosciences Inc at Stifel Healthcare Conference

Latest Developments

More

Catalyst Biosciences Q3 Loss Per Share $1.06

Catalyst Biosciences Says Cash, Cash Equivalents And Short-Term Investments, As Of Sept 30 Were $85 Mln

Catalyst Biosciences Announces Transition Of CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catalyst Biosciences Inc

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Industry

Biotechnology & Drugs

Contact Info

611 Gateway Blvd Ste 710

+1.650.8710761

http://www.catalystbiosciences.com/

Executive Leadership

Augustine J. Lawlor

Independent Chairman of the Board

Nassim Usman

President, Chief Executive Officer, Director

Andrew Hetherington

Senior Vice President - Technical Operations

Grant Blouse

Vice President - Translational Research

Jeffrey Landau

Vice President - Business Development

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-21.750

2017

-7.450

2018

-2.680

2019(E)

-4.540
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.78
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.78
LT Debt To Equity (MRQ)
1.78
Return on Investment (TTM)
-49.25
Return on Equity (TTM)
-46.54

Latest News

Latest News

BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share $0.56

* CATALYST BIOSCIENCES REPORTS FIRST QUARTER OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Catalyst Biosciences Receives $1.5 Million For Neuronal Nicotinic Receptor Asset

* CATALYST BIOSCIENCES RECEIVES $1.5 MILLION IN TWO MILESTONE PAYMENTS FOR NEURONAL NICOTINIC RECEPTOR (NNR) ASSET Source text for Eikon: Further company coverage:

BRIEF-Catalyst Biosciences Provides Corporate Update

* CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D

* CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D

BRIEF-Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences

* RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 Source text: (http://bit.ly/2nDJSqt) Further company coverage:

BRIEF-Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln

* CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text - http://bit.ly/2F2CQC6 Further company coverage:

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS

BRIEF-Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences

* NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING Source text : (http://bit.ly/2l9OsLV) Further company coverage:

BRIEF-Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Catalyst Biosciences Appoints Edward Williams To Its Board

* CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS

BRIEF-Catalyst biosciences Q3 loss per share $1.34

* Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update

BRIEF-Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration

* Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases

BRIEF-Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017

* Catalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B

BRIEF-Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

* Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

BRIEF-Catalyst Biosciences Inc announces issuance of Asia patents covering Factor IX Hemophilia Program

* Catalyst Biosciences Inc - announces issuance of Asia patents covering factor IX Hemophilia Program Source text for Eikon: Further company coverage:

BRIEF-Catalyst Biosciences' reports positive data on hemophilia B drug

* Catalyst Biosciences announces positive factor ix clinical data

BRIEF-Catalyst Biosciences posts Q2 loss of $2.53 per share

* Catalyst biosciences reports second quarter 2017 financial results and provides subcutaneous (sq) hemophilia program update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up